Vor Biopharma (VOR) news
Recent news
Google built-in now spans 16 brands, 100+ car models
Google's integration of its Android-based infotainment system into the automotive industry has expanded significantly, now spanning 16 car brands and over 100 vehicle models. This development marks a major milestone in the company's strategy to establish a dominant presence in the connected car…
AInvest Wire · 1d agoNvidia also investing in Entalpic
Nvidia has expanded its investment portfolio by allocating significant capital to Entalpic, a startup specializing in AI-driven materials and chemistry research. The investment aligns with Nvidia’s broader strategy to integrate AI and accelerated computing into scientific and engineering workflows,…
AInvest Wire · 1d agoMohamed Aiman Kamal El Din Mohamed Abdul Khaliq Korra sells 34.2 mln shares in Korra Holding for EGP 205.3 mln - EGX
Mohamed Aiman Kamal El Din Mohamed Abdul Khaliq Korra has sold 34.2 million shares in Korra Holding (KORA) for a total value of EGP 205.3 million, according to recent data from the Egyptian Exchange . The transaction reflects significant activity in the stock, which has seen a recent decline in…
AInvest Wire · 1d agoBiogen shares rise 2.1% premarket after JP Morgan raises to overweight from neutral
Biogen Inc. (NASDAQ: BIIB) shares rose 2.1% in premarket trading on October 12, 2026, following an upgrade from JP Morgan, which raised its rating on the stock to "overweight" from "neutral." The move comes amid growing optimism about Biogen's pipeline and upcoming data readouts, which are seen as…
AInvest Wire · 2d agoBio-pharmaceutical stocks fell in regular trading, with Eton Pharmaceuticals down 3.3%, Livent down 5.0% and BioTelemetry down 6.2%.
On September 30, 2026, bio-pharmaceutical stocks experienced declines in regular trading, with several companies posting notable losses. Eton Pharmaceuticals fell 3.3%, Livent dropped 5.0%, and BioTelemetry declined by 6.2%. The sector has faced ongoing scrutiny due to stretched valuations and…
AInvest Wire · Sep 30, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.